Company Overview
About Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
Business Model & Competitive Advantage
Pliant's lead asset bexotegrast (PLN-74809) is a dual αvβ6/αvβ1 inhibitor advancing in Phase 2b/3 trials for IPF — a fatal lung scarring disease with median survival of 3–5 years after diagnosis. IPF affects 100,000+ U.S. patients with two approved therapies that only slow progression. Bexotegrast's Phase 2 data showed lung function stabilization and biomarker improvements that have sustained investor and partner interest.
Competitive Landscape 2025–2026
Listed on Nasdaq since 2019, Pliant has established itself as the leading pure-play integrin inhibitor company for fibrosis. The company's pipeline extends to liver fibrosis (PSC, MASH) and kidney fibrosis, targeting markets where no approved anti-fibrotic therapies exist and where integrin biology is well-validated by genetics and preclinical models.
Open Positions
Reddit Discussions
Key Differentiators
Strong Challenger
Pliant Therapeutics is an established challenger with significant market presence and competitive offerings in BioTech.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Adobe Firefly
Adobe Firefly is Adobe's generative AI platform and suite of creative AI tools, launched in March 2023 as Adobe's flagship response to the generative AI revolution. Firefly was purpose-built to be com
80 Acres Farms
80 Acres Farms is a commercial-scale indoor vertical farming company that, following its merger with Soli Organic, operates the largest indoor farming network in North America. The company raised $115
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Compare Pliant Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Pliant Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Pliant Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Pliant Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →